News Roche breast cancer trial success could kill Puma's rival Perjeta trial success sends rival biotech's share price crashing.
News Pfizer breast cancer drug Ibrance rejected by NICE Ibrance too expensive at almost £80,000 per course.
News Call for Roche to lower Kadcyla price further after NICE rej... Ruling could end funding for cancer drug in England.
Novartis Strong phase 3 data boosts Novartis' Ibrance rival Ribociclib will compete against Pfizer's breast cancer blockbuster
News Pfizer fears rough ride with NICE over breast cancer drug Concerns over NICE's treatment of add-on therapies.
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
